Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 9, Pages 2129
Publisher
MDPI AG
Online
2022-09-01
DOI
10.3390/biomedicines10092129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial
- (2022) Elizabeth R Volkmann et al. RHEUMATOLOGY
- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox
- (2022) Alexandra Nagy et al. Biomedicines
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2022) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
- (2021) Kristin B Highland et al. Lancet Respiratory Medicine
- Natural variability in the disease course of SSc-ILD: implications for treatment
- (2021) Madelon C. Vonk et al. European Respiratory Review
- Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study
- (2021) Vasiliki-Kalliopi Bournia et al. RHEUMATOLOGY INTERNATIONAL
- Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
- (2021) Alexandra Nagy et al. Frontiers in Pharmacology
- Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
- (2020) Anna-Maria Hoffmann-Vold et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease
- (2019) Eniko Barczi et al. ADVANCES IN THERAPY
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
- (2019) Aurore Bergamasco et al. Clinical Epidemiology
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- (2019) Kevin R. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies
- (2019) Elizabeth T Thomas et al. BMJ Open
- Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
- (2019) Dinesh Khanna et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach
- (2018) Balazs Odler et al. Frontiers in Physiology
- Idiopathic pulmonary fibrosis
- (2017) Luca Richeldi et al. LANCET
- Systemic sclerosis
- (2017) Christopher P Denton et al. LANCET
- Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
- (2017) Jasmine Z. Cheng et al. RESPIROLOGY
- Update of EULAR recommendations for the treatment of systemic sclerosis
- (2016) Otylia Kowal-Bielecka et al. ANNALS OF THE RHEUMATIC DISEASES
- Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis
- (2016) Els Vandecasteele et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- (2016) Donald P Tashkin et al. Lancet Respiratory Medicine
- Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease
- (2014) Tiffany A. Winstone et al. CHEST
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
- (2013) Brett Ley et al. ANNALS OF INTERNAL MEDICINE
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
- (2013) Frank van den Hoogen et al. ANNALS OF THE RHEUMATIC DISEASES
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma
- (2009) M. C. GARIN et al. JOURNAL OF RHEUMATOLOGY
- Interstitial Lung Disease in Systemic Sclerosis
- (2008) Nicole S. L. Goh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started